US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that the Phase 3 TroFuse-015 trial evaluating investigational drug sacituzumab tirumotecan (sac-TMT) met its primary endpoint of overall survival (OS) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two previous lines of systemic therapy.
The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with treatment of physician's choice, making sac-TMT the first TROP2-directed antibody-drug conjugate (ADC) to demonstrate an overall survival benefit in this patient population in a global Phase 3 study.
However, the trial did not meet the secondary endpoint of progression-free survival assessed by blinded independent central review. Objective response rates showed a nominal improvement in favour of sac-TMT, and the safety profile remained consistent with previous studies, with no new safety signals identified.
Merck plans to present the findings at an upcoming medical meeting and share the data with regulatory authorities. TroFuse-015 represents the second positive Phase 3 readout from the company's TroFuse development programme, which comprises 18 ongoing global Phase 3 trials evaluating sac-TMT across multiple cancer types and treatment settings.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial